LON:GENI GENinCode (GENI) Share Price, News & Analysis → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Free GENI Stock Alerts GBX 8.75 0.00 (0.00%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range 8.55▼ 950-Day Range 3.34▼ 9.4052-Week Range 3.34▼ 17Volume30,601 shsAverage Volume309,940 shsMarket Capitalization£15.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsStock AnalysisChartCompetitors Get GENinCode alerts: Email Address Ad AltimetrySecret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. About GENinCode Stock (LON:GENI)GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.Read More GENI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GENI Stock News HeadlinesOctober 30, 2023 | finance.yahoo.comCARDIO inCode Study Results Presented at ESC Annual MeetingAugust 16, 2023 | marketwatch.comGENinCode Shares Rise on FDA Filing for Heart Disease Test KitApril 20, 2024 | Altimetry (Ad)Secret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. July 19, 2023 | lse.co.ukGENinCode and MedStar collaborate on coronary heart disease testingJuly 19, 2023 | marketwatch.comGENinCode Collaborates With MedStar Health for Coronary Heart Disease TestJuly 14, 2023 | msn.comGenetic testing could bring in ‘new age’ of diagnostics in NHSJune 6, 2023 | lse.co.ukGENinCode annual loss widens; focuses on US, EU, and NHS in UKMay 21, 2023 | finance.yahoo.comShould You Investigate Genius Sports Limited (NYSE:GENI) At US$5.18?April 20, 2024 | Altimetry (Ad)Secret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. May 2, 2023 | lse.co.ukUK National Health Service to hike use of GENinCode heart disease testMay 2, 2023 | marketwatch.comGENinCode's Heart Disease Test Gets Accelerated Use in UK; Shares RiseJanuary 3, 2023 | lse.co.ukGENinCode shares surge amid state licence approval for California labOctober 21, 2022 | finance.yahoo.comGenius Sports (NYSE:GENI) shareholders have endured a 78% loss from investing in the stock a year agoSeptember 29, 2022 | lse.co.ukEARNINGS UPDATES: Transence Tech swings to profit; Curzon widens lossAugust 5, 2022 | ca.finance.yahoo.comGENinCode plc (GENI.L)July 8, 2022 | uk.investing.comShenzhen Techwinsemi Technology Co Ltd (001309)July 8, 2022 | uk.investing.comNordic Lights Group Oy (NORDLIG)July 3, 2022 | lse.co.ukDas (RBI): "Cryptocurrencies are a clear danger, their value is based on fantasy"July 3, 2022 | lse.co.ukUPDATE: Braemar Shipping delays publication of results; outlook goodSee More Headlines Receive GENI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENinCode and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:GENI CUSIPN/A CIKN/A Webwww.genincode.com Phone44 1865 955 847FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-6,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.23% Return on Assets-43.64% Debt Debt-to-Equity Ratio6.74 Current Ratio5.92 Quick Ratio15.89 Sales & Book Value Annual Sales£1.72 million Price / Sales9.00 Cash FlowGBX 10.50 per share Price / Cash Flow0.83 Book ValueGBX 5 per share Price / Book1.75Miscellaneous Outstanding Shares176,960,000Free FloatN/AMarket Cap£15.48 million OptionableNot Optionable Beta0.40 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Matthew Heaton Walls (Age 60)Co-Founder, CEO & Director Comp: $336.54kMr. Jordi Puig Gilberte (Age 49)Co-Founder, COO & Director Comp: $149.16kMr. Paul Andrew Peter Foulger (Age 55)CFO, Company Secretary & Director Comp: $150.07kKey CompetitorsYourgene HealthLON:YGENAbingdon HealthLON:ABDXVerici DxLON:VRCIProteome SciencesLON:PRMLungLife AILON:LLAIView All Competitors GENI Stock Analysis - Frequently Asked Questions How have GENI shares performed in 2024? GENinCode's stock was trading at GBX 5.25 at the beginning of the year. Since then, GENI stock has increased by 66.7% and is now trading at GBX 8.75. View the best growth stocks for 2024 here. How do I buy shares of GENinCode? Shares of GENI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:GENI) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENinCode Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.